Intravenous immunoglobulin induced pancytopenia while preventing development of gestational alloimmune liver disease: A case report

Minhazur Sarker, Chelsea DeBolt, Noel Strong

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Gestational alloimmune liver disease is a rare complication associated with reactive maternal immunoglobulins resulting in neonatal liver pathology. The mainstay treatment for prevention in future pregnancies is intravenous immunoglobulins. Although relatively well tolerated, adverse reactions may occur. In this report, we highlight a case of intravenous immunoglobulin induced pancytopenia diagnosed by exclusion after thorough work-up. The patient was counseled on options and an informed decision was made to proceed with re-trial of intravenous immunoglobulin without systemic prednisone. This resulted in the delivery of a healthy neonate. We propose that future adverse reactions to intravenous immunoglobulin in pregnancy may warrant the trial of a new medication lot and use of systemic steroids only if subsequently indicated.

Original languageEnglish
Article numbere00422
JournalCase Reports in Women's Health
Volume35
DOIs
StatePublished - Jul 2022

Keywords

  • Case report
  • Gestational alloimmune liver disease
  • Intravenous immunoglobulin
  • Pancytopenia

Fingerprint

Dive into the research topics of 'Intravenous immunoglobulin induced pancytopenia while preventing development of gestational alloimmune liver disease: A case report'. Together they form a unique fingerprint.

Cite this